Exploring Thrombotic Risk Factors at the Molecular Level

Start year: 2025

Summary: [My Research Vision] The ambition over the next five years is to revolutionise thrombotic disease management by refining and integrating advanced imaging and microfluidic technologies. The goal is to standardize, streamline, and reduce the cost of point-of-care testing (POCT) for high-risk populations, shifting from lab bench to bedside applicability. Specifically, I will advance integrin biology on blood clotting platelets at the molecular level; evaluate the performance of novel anti-thrombotic drugs currently under clinical trials with a cohort of 1,000 blood donors; and translate into a “Blood Clotting Imaging Chamber (BCIC)” for prophylaxis, drug screen and prognosis for thrombotic diseases. This paradigm shift towards nano- and micro-technology-based diagnostics and prognostics will enable personalised, precise, and timely interventions in thrombosis.